ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pegcetacoplan

Also written as “Pegcetacoplan”, “APL-2” and “PEGCETACOPLAN (APL-2)”.

Its studies are mostly in Geographic Atrophy · Hemoglobinuria, Paroxysmal · Glomerulonephritis, Membranoproliferative · Anemia, Hemolytic, Autoimmune · Macular Degeneration, led by 4 companies.

Drug pagePegcetacoplan: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 10, 201830 company-led studies, 7 open or runningNext primary completion: Jun 25, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen244 open or runningphase 3since Apr 10, 2018Oct 8, 2014Jun 25, 2027phase 2 · NCT07215390
Swedish Orphan Biovitrumits history only42 open or runningphase 4since Mar 26, 2026Oct 15, 2021Jan 17, 2031phase 3 · NCT07898774
AbbVieits history only11 open or runningphase 2since Aug 12, 2025Aug 12, 2025Oct 2029phase 2 · NCT07160179
Hoffmann-La Rocheits history only10 open or runningphase 1since Apr 29, 2025Apr 29, 2025none ahead

Also a collaborator on its studies: IQVIA Pty.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Biogen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 7 earlier studies, Oct 8, 2014 to Mar 8, 2018.

  1. Dec 9, 2017Named pegcetacoplanINNProposed as its International Nonproprietary Name in WHO's List 118
  2. Apr 10, 20183 phase 3 studiesNCT03500549, NCT03525613, NCT03525600
  3. May 9, 2018Phase 3 study in PNHNCT03531255 · 137 enrolled · United States, Australia, Belgium and more
  4. Jun 28, 2018Phase 2 study in Hemoglobinuria, ParoxysmalNCT03593200 · 4 enrolled · Bulgaria, Serbia
  5. Dec 14, 2018Phase 1 study in Geographic AtrophyNCT03777332 · 19 enrolled · United States
  6. Sep 9, 2019Phase 3 study in Hemoglobinuria, ParoxysmalNCT04085601 · 53 enrolled · Colombia, Hong Kong, Malaysia and more
  7. Sep 22, 20202 phase 2 studiesNCT04579666, NCT04572854
  8. Feb 23, 2021Phase 3 study in Geographic Atrophy Secondary to Age-related Macular DegenerationNCT04770545 · 792 enrolled · United States, Argentina, Australia and more
  9. Mar 8, 2021Phase 2 study in Hemoglobinuria, ParoxysmalNCT04901936 · 12 planned · United States, Czechia, France and more
  10. Sep 23, 2021Phase 3 study in Glomerulonephritis, MembranoproliferativeNCT05067127 · 124 enrolled · United States, Argentina, Australia and more
  11. Mar 30, 2023Phase 3 study in Glomerulonephritis, MembranoproliferativeNCT05809531 · 100 enrolled · United States, Argentina, Australia and more
  12. Jun 6, 2025Phase 3 study in Delayed Graft FunctionNCT07020832 · Brazil
  13. Jun 30, 2025Phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationNCT07215390 · 240 planned · United States
  14. Sep 15, 2025Phase 3 study in FSGSNCT07213960 · 270 planned · United States
  15. Oct 6, 2025Phase 3 study in Geographic AtrophyNCT07214740 · 44 enrolled · United States

Ahead

  1. Jun 25, 2027Primary completion: phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationNCT07215390
  2. Jul 2027Primary completion: phase 3 study in Glomerulonephritis, MembranoproliferativeNCT05809531
  3. Dec 2028Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT04901936
  4. Oct 2029Primary completion: phase 3 study in FSGSNCT07213960

TargetBeta

C3 →read by rule
“A pegylated peptide inhibitor of human complement components C3 and C3b, ”NCIt, by rule
“Complement C3 inhibitor”ChEMBL 37, by rule

Other programs on C3

ProgramCompanyFurthest phaseStudies
SSS55rule3SBiophase 11

Studies

All 24 Biogen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07214740Geographic Atrophy · United States3CompletedDec 12, 202544
NCT07213960FSGS · United States3RecruitingOct 2029270
NCT07215390Geographic Atrophy Secondary to Age-related Macular Degeneration · United States2RecruitingJun 25, 2027240
NCT07020832Delayed Graft Function · Brazil3WithdrawnJun 20290
NCT05809531Glomerulonephritis, Membranoproliferative · United States, Argentina, Australia and more3Active, not recruitingJul 2027100
NCT05067127Glomerulonephritis, Membranoproliferative · United States, Argentina, Australia and more3CompletedJun 26, 2024124
NCT04901936Hemoglobinuria, Paroxysmal · United States, Czechia, France and more2RecruitingDec 202812
NCT04770545Geographic Atrophy Secondary to Age-related Macular Degeneration · United States, Argentina, Australia and more3CompletedSep 5, 2025792
NCT04572854Glomerulonephritis, Membranoproliferative · United States, Argentina, Australia and more2CompletedFeb 27, 202313
NCT04579666Amyotrophic Lateral Sclerosis · United States, Australia, Belgium and more2TerminatedMar 31, 2023249
NCT04085601Hemoglobinuria, Paroxysmal · Colombia, Hong Kong, Malaysia and more3CompletedJun 23, 202153
NCT03777332Geographic Atrophy · United States1CompletedApr 1, 202119
NCT03593200Hemoglobinuria, Paroxysmal · Bulgaria, Serbia2CompletedOct 22, 20194
NCT03531255PNH · United States, Australia, Belgium and more3CompletedSep 4, 2025137
NCT03525613Geographic Atrophy · United States, Australia, Brazil and more3CompletedJun 28, 2021637
NCT03525600Geographic Atrophy · United States, Argentina, Australia and more3CompletedJun 21, 2021621
NCT03500549Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more3CompletedNov 14, 201980
NCT03465709Neovascular Age-related Macular Degeneration · United States2TerminatedApr 5, 201917
NCT03453619Glomerulonephritis, IGA · United States2CompletedApr 16, 202021
NCT03226678Anemia, Hemolytic, Autoimmune · United States2CompletedSep 12, 202224
NCT02588833Hemoglobinuria, Paroxysmal · Hong Kong, Malaysia, New Zealand and more1CompletedAug 26, 201923
NCT02503332Geographic Atrophy · United States, Australia, New Zealand2CompletedJul 14, 2017246
NCT02461771Neovascular Age-Related Macular Degeneration · United States, Australia1CompletedMar 8, 201613
NCT02264639Hemoglobinuria, Paroxysmal · United States1CompletedOct 22, 20189

How it is read

Names in the registry

  • “Pegcetacoplan”, 17 entries
  • “APL-2”, 7 entries
  • “PEGCETACOPLAN (APL-2)”, 2 entries
  • “APL-3007, pegcetacoplan (APL-2)”, 2 entries
  • “Syfovre™”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.